In this article, I have evaluated prominent biotech stocks, Bionano Genomics, Inc. (BNGO) and Gilead Sciences, Inc. (GILD), to determine which could generate better returns. After thoroughly evaluating these stocks, I think while GILD could be a solid buy, avoiding BNGO could be ideal for the reasons discussed in this article.
Government support, including regulatory modernization and increased healthcare spending, is driving the biotechnology industry. The rise of personalized medicine and orphan drug formulations is creating opportunities for innovative biotech firms, further boosting market revenue.
